Results of multi-institutional clinical study published in peer reviewed journal ‘Cancers’ confirms efficacy of Oxford BioDynamics’ EpiSwitch ® blood-based Colorectal No-Stool Test (NST) High accuracy ...

Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...

Mark Stenhouse left his executive role at AbbVie to join Exact Sciences because he felt the company was fighting a worthy battle: preventing colorectal cancer. Mr. Stenhouse, now Exact Science’s ...

WASHINGTON -- A blood-based test for the early detection of colorectal cancer (CRC) met its prespecified sensitivity and specificity endpoints, according to results from the PREEMPT CRC study. Using ...

– Study met all primary endpoints, including 79.2% sensitivity for colorectal cancer (CRC) and 91.5% specificity for non-advanced colorectal neoplasia – – PREEMPT CRC, the largest study of a ...

Colorectal cancer (CRC), more commonly called colon cancer, is currently the second-leading cause of cancer-related death in the U.S. But studies find it’s also highly treatable, especially if it’s ...

Although the FDA approval of Guardant Health’s Shield blood test provides an appealing alternative to other colorectal cancer screening methods, the advantages and disadvantages should be highlighted ...

Offering a blood test to people who have declined both a colonoscopy and a fecal immunochemical test (FIT) increased colorectal cancer (CRC) screening by 7.5% without decreasing use of the preferred ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “More than three out of four Americans who die from ...

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...

The FDA has approved the Cologuard Plus test, a next-generation, multitarget stool DNA test approved for patients at an average risk for colorectal cancer. The FDA’s approval was based on findings ...

Offering a blood test as a secondary option in individuals who previously declined colonoscopy or FIT increased CRC screening by 7.5%. There was no decrease in uptake of first-line screening options.